Editor's note: TipRanks is a tech company that ranks analysts and financial bloggers based on their picks' performance. The goal of this piece is to highlight an analyst that you likely have never heard of who has a great track record.
As baby boomers continue to transition out of the workforce, home health-care companies are thriving and expanding throughout the country.
Shares of Amedisys (AMED) are experiencing a pullback, down 18 percent year to date. In light of the depressed share prices, Michael Wiederhorn of Oppenheimer is upgrading the company from "hold" to "buy," pointing to its long-term potential and disciplined management.
Wiederhorn is currently the top performing analyst on Wall Street out of more than 3,600 analysts. He has a 63 percent success rate recommending stocks with an average return of 17 percent one year after his recommendation.
Although the company does not receive a lot of media attention, Wiederhorn points to three reasons to add Amedisys to your portfolio: